The Proportion of Rifabutin-susceptible Strains among Rifampicin- resistant Isolates and Its Specific rpoB Mutations

Woo-Jin LEW; Young-Kil PARK; Hee-Jin KIM; Chulhun CHANG; Gill-Han BAI; Sung-Kyu KIM.
Tuberculosis and Respiratory Diseases ; : 257-265, 2005.
Artículo en Ko | WPRIM | ID: wpr-25288

Documentos relacionados

  1. Rifabutin for treating tuberculosis in solid organ transplant recipients: A retrospective observational study and literature review.
  2. Drug-drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model.
  3. Rifabutin: where do we stand in 2016?
  4. The Inappropriateness of Using Rifampicin E-Test to Predict Rifabutin Resistance in Helicobacter pylori.
  5. Rifabutin but not rifampicin can partly out-balance P-glycoprotein induction by concurrent P-glycoprotein inhibition through high affinity binding to the inhibitory site.
  6. Structural diversity and biological relevance of benzenoid and atypical ansamycins and their congeners.
  7. Mycobacterium abscessus HelR interacts with RNA polymerase to confer intrinsic rifamycin resistance.
  8. Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.
  9. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?
  10. Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy.